World Sleep Industry ENCYCLOPEDIA

Sleep Data Asset Valuation Services

6.4.3

1. Definition, purpose and basis of value

Sleep data asset valuation services analyze, estimate and report the value of sleep data resources that a specified entity lawfully owns or controls, can measure in monetary terms and may use to obtain direct or indirect economic benefit. The engagement first defines its purpose, subject, bundle of interests, basis of value and valuation date. A subject may be a polysomnography repository, longitudinal wearable data, device telemetry, an annotated cohort, a training dataset, derived measures or a data product, but it must be identified by version, scope and rights.

Purposes may include a transaction, license, capital contribution, financing, state-asset administration, loss measurement, enterprise valuation or internal planning. Each purpose can require a different basis, assumptions, procedure and intended user, and the same data generally have different value in different use cases. The conclusion is a professional opinion at a date under stated assumptions. It is not automatically carrying amount, transaction price, future revenue, borrowing capacity or regulatory approval. Consulting calculations, internal scores and an asset valuation report issued under the applicable professional regime should be distinguished.

2. Subject, bundle of interests and prerequisite review

The valuer needs a subject manifest stating name, content, fields, period, population, granularity, provenance, refresh rate, processing lineage, quality, storage, version hash, product form and related systems. Sleep data require device and sensor position, sampling rate, channels, valid duration, scoring rules, label source, reference standard, nights per person, age and condition mix. The phrase “sleep database” does not make a conclusion reproducible.

Rights review should identify whether the entity holds or controls resource possession, processing use, product operation, contractual license, intellectual property, trade secrets or another economic interest, with territory, field, term, exclusivity, sublicensing, deletion and individual-rights constraints. Evidence can include collection and generation records, contracts, authorization, notices and consent, ethics material, registration certificates and past transactions. A certificate is evidence but not a substitute for rights and compliance diligence. An unlawful source, unresolved dispute, missing processing basis or inability to control use should lead to a narrower subject, a clearly disclosed special assumption or refusal to issue a misleading value.

3. Sleep-data quality and use-case value drivers

Value drivers should cover cost, use case, market and quality. General quality dimensions include accuracy, consistency, completeness, conformance, freshness and accessibility. Sleep-specific measures include signal loss, valid duration, channel completeness, event and stage label agreement, reliability of the reference, person-level duplication, device diversity, population representativeness and stability across nights. Record volume, hours and unique persons should be separated, and algorithm performance is not a substitute for assessing the data.

Use-case value depends on whether the resource improves a defined decision, such as device quality monitoring, cohort discovery, algorithm training and validation, clinical workflow support or patient service. The analysis should identify users, deployment context, sector entry conditions, substitute data, complementary technology, refresh ability and the models, people, compute, channels and other assets required to realize benefit. Health information, children’s data, rare conditions and re-identifiable waveforms introduce use constraints and protection costs. Greater sensitivity does not imply a higher price; a resource that cannot lawfully and safely serve its intended use may have materially lower economic value.

4. Income, cost and market approaches

The income approach is appropriate when future economic benefits can be predicted with reasonable support. Direct income, royalties, excess returns, incremental revenue or cost savings may be considered, but the contribution of data must be separated from brands, devices, algorithms, teams, channels and other contributory assets. Forecasts must match the valued interest. The benefit period should reflect contracts, legal limits, refresh and obsolescence, product life and substitution. The discount rate should capture management, circulation, security, regulatory, market and technical risk. Applying an arbitrary percentage to total business revenue overstates data contribution.

The cost approach starts with the current cost to recreate data of equivalent utility, including appropriate planning, direct, indirect, opportunity and tax components, followed by quality, functional and economic adjustments. Historical expenditure is not necessarily replacement cost and is not value. Failed collection, duplicate records, rework and costs shared with the main business require careful attribution. The market approach requires lawful, sufficiently comparable transactions. Rights, transaction mode, scale, use, geography, term, quality, supply and demand and date need adjustment. Asking prices, press reports of appraisals and bundled deal totals are not direct evidence of comparable consideration.

5. Assumptions, risk and sensitivity

Data values are assumption-sensitive. The report should identify and source assumptions about users and calls, price, renewal, refresh cost, compute, quality improvement, compliance spending, competition and economic life. For sleep data without commercial history, a large market or generic demand for artificial intelligence does not replace evidence from customers, pilots and conversion. Scarcity should be tested alongside substitutability. A rare cohort may still be hard to monetize because it is small, biased, restricted or unreliably labeled.

Sensitivity work should test effective sample share, useful life, license price, customer retention, revenue attribution, discount rate, maintenance cost and regulatory constraints. Scenario or probability techniques can express uncertainty, with clear disclosure of whether the result is a point or range. The risk register should include provenance and rights, personal information, important data, cross-border issues, breach, quality drift, device obsolescence, model leakage, market concentration and customer dependency. A discount-rate premium cannot cure every risk. A fact that makes the proposed use unlawful or infeasible is a prerequisite issue, not merely another percentage.

6. Professional process, report and independence

A sound process includes engagement acceptance, conflict checks, an engagement agreement, definition of purpose and scope, site or system investigation, collection and verification, quality assessment, approach selection, calculation and cross-checking, internal review, reporting and record retention. Institutions and professionals performing regulated asset valuation must remain independent, objective and impartial and should not accept a predetermined number. Unless the applicable standards support only one method, appropriate methods should be analyzed and used as required, with differences and the reason for the final conclusion explained.

The report should disclose the subject and interests, date, purpose, basis, quality assessment, use case and restrictions, economic and industry context, information sources, expert work, methods, parameters, assumptions, sensitivities and material risks. Raw sleep records need not be exposed in a public report; controlled verification, summaries and third-party quality work can support the conclusion. The client is responsible for the truth, completeness and legality of supplied information, while the valuer still performs verification. Personal information, trade secrets and security-sensitive materials require restricted access, minimized disclosure and protected files.

7. Use of results, reassessment and procurement acceptance

The report is for its stated users, purpose and conditions. Accounting, tax, state-asset, transaction and financing uses still require their own rules, approvals and professional judgments; a large valuation does not create a recognizable asset or pledged cash flow automatically. Transaction price remains a function of supply, demand, contract rights, diligence and negotiation. External quotations should include the valuation date, subject, interests and key assumptions. Quoting only the amount for marketing, repeated financing or a new, unvalued version is misleading.

Material refreshes, rights changes, expiry, quality drift, incidents, rule changes, new market evidence and business-model divergence can trigger reassessment or impairment review. Procurement should verify the firm’s filing status, personnel, independence, sector and data capability, subcontracting and information security; fees should not be directly contingent on the concluded value. Acceptance should assess process, evidence, reproducibility, method fit, sensitivity and disclosure—not whether management’s target was reached. If evidence is insufficient, a reservation, wider range, delay or inability to reach a reliable conclusion can be the responsible result.